{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:56:40Z","timestamp":1758815800950},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>We investigated the association of 5\u03b1\u2010reductase inhibitor (5\u2010ARI) treatment with pathologic and biochemical outcome among the contemporary prostate cancer (PCa) patients undergoing radical prostatectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We reviewed records of 1,204 men who underwent radical prostatectomy from 2003 to 2010. We estimated association of 5\u2010ARI use with high (\u22657) pathologic Gleason score and pathologically nonorgan\u2010confined disease (\u2265pT3) via logistic regression, and biochemical outcome via Cox proportional hazards regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 1,204 patients, 50 (4.2%) reported having history 5\u2010ARI treatment before radical prostatectomy. Median duration of 5\u2010ARI treatment among the 50 patients was 23.0 months. When adjusted for various factors including age, body mass index, prostate\u2010specific antigen, clinical stage, biopsy Gleason, and prostate volume, history of 5\u2010ARI treatment was revealed to be significantly associated with high (\u22657) pathologic Gleason score (<jats:italic>P<\/jats:italic>\u2009=\u20090.015). Also, 5\u2010ARI use was observed to significantly associated with higher rates of extraprostatic extension of tumor (<jats:italic>P<\/jats:italic>\u2009=\u20090.005) and seminal vesicle invasion (<jats:italic>P<\/jats:italic>\u2009=\u20090.003), respectively, when adjusted for same variables. However, 5\u2010ARI use was not demonstrated to be a significant preoperative predictor of biochemical recurrence\u2010free survival in multivariate analysis (<jats:italic>P<\/jats:italic>\u2009=\u20090.528).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Our results showed 5\u2010ARI treatment may be associated with more aggressive PCa demonstrating higher pathologic Gleason score and advanced pathologic tumor stage in men undergoing radical prostatectomy. However, further investigations via larger\u2010scale, prospective studies would be needed on the actual effect of 5\u2010ARI treatment on PCa\u2010specific morbidity and mortality. Prostate 72:1187\u20131192, 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.22468","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T21:11:19Z","timestamp":1323292279000},"page":"1187-1192","source":"Crossref","is-referenced-by-count":4,"title":["Association of 5\u03b1\u2010reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy"],"prefix":"10.1002","volume":"72","author":[{"given":"Sung Kyu","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangchul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok\u2010Soo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheeyoung","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1106783"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030660"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908127"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_6_6_2","volume-title":"The Asia\u2010Pacific perspective: Redefining obesity and its treatment","author":"World Health Organization, Western Pacific Region, International Association for the Study of Obesity","year":"2000"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.10.097"},{"key":"e_1_2_6_8_2","unstructured":"Food and Drug Administration.Briefing information and slides presented at the December 1 2010 meeting of the Oncologic Drugs Advisory Committee.http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm195226.htm."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22116"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.048"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09814.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.05.045"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07061.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200007000-00004"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.008"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.155"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.052"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181216.71605.38"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05375.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20499"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22468","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.22468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T21:17:52Z","timestamp":1697663872000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.22468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/pros.22468"],"URL":"https:\/\/doi.org\/10.1002\/pros.22468","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}